Cripto-1 Overexpression May Increase Risk of Bladder Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Tumor Biology, researchers have found Cripto-1, an embryonic gene, overexpression may play role in the development of bladder cancer and may have value as a possible prognostic biomarker in patients with bladder cancer.
For the study, researchers sought to investigate the significance of Cripto-1 expression in patients with bladder cancer. To do so, the researchers compared tissue samples of cancerous bladders and noncancerous bladders. They found that Cripto-1 was overexpressed in bladder cancer tissue samples and greatly linked with tumor size (P = 0.003) and tumor grade (P = 0.001).
Furthermore, Cripto-1 overexpression was significantly linked with SRY-related HMG-box gene 2 expression (P = 0.003) and Ki-67 (P = 0.001). SRY-related HMG-box gene 2 regulates gene expression in the stomach and Ki-67 is strongly associated with cell proliferation.
In addition, bladder cancer samples with high Cripto-1 levels were more likely associated with decreased recurrence/metastasis-free survival compared with samples with low Cripto-1 levels (P = 0.011). Statistical analyses demonstrated that Cripto-1 may be a prognostic marker for recurrence/metastasis-free survival (P = 0.036).
Cripto-1 gene overexpression may play role in the development of bladder cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed